Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Dawn Swan, Mark E. Gurney, Janusz Krawczyk, et al.
HemaSphere (2020) Vol. 4, Iss. 2
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Tumour burden and efficacy of immune-checkpoint inhibitors
Filippo Gustavo Dall’Olio, Aurélien Marabelle, Caroline Caramella, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 75-90
Closed Access | Times Cited: 216
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
Veronica Finisguerra, Tereza Dvořáková, Matteo Formenti, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 5, pp. e005719-e005719
Open Access | Times Cited: 52
The future of cancer immunotherapy: DNA vaccines leading the way
Aanshi J. Pandya, Yesha Shah, Nirjari Kothari, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Open Access | Times Cited: 42
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 4, pp. 354-369
Open Access | Times Cited: 72
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Dawn Swan, Philip Murphy, Siobhán Glavey, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1819-1819
Open Access | Times Cited: 32
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
Andrea Díaz-Tejedor, Mauro Lorenzo-Mohamed, Noemí Puig, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1353-1353
Open Access | Times Cited: 39
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
Grace Lassiter, Cole Bergeron, Ryan Guedry, et al.
Current Oncology (2021) Vol. 28, Iss. 1, pp. 640-660
Open Access | Times Cited: 38
Effects of Bifidobacterium animalis subsp. lactis IU100 on Immunomodulation and Gut Microbiota in Immunosuppressed Mice
Limian Zhou, Xindi Yin, Bing Fang, et al.
Microorganisms (2024) Vol. 12, Iss. 3, pp. 493-493
Open Access | Times Cited: 6
Genome Instability in Multiple Myeloma: Facts and Factors
Anna Y. Aksenova, Anna S. Zhuk, Artem G. Lada, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 5949-5949
Open Access | Times Cited: 30
The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma
Panagiotis Malamos, Christina Papanikolaou, Maria Gavriatopoulou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6991-6991
Open Access | Times Cited: 4
Effect of sakuranetin against cyclophosphamide-induced immunodeficiency mice: role of IFN-γ/TNF-α/IgG/IgM/interleukins
Khalid Saad Alharbi, Sattam Khulaif Alenezi, Tariq G. Alsahli, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Ginseng–Astragalus–oxymatrine injection ameliorates cyclophosphamide-induced immunosuppression in mice and enhances the immune activity of RAW264.7 cells
Yuangeng Li, Ping Yu, Wenwen Fu, et al.
Journal of Ethnopharmacology (2021) Vol. 279, pp. 114387-114387
Closed Access | Times Cited: 27
Immunomodulatory Effects of a Standardized Botanical Mixture Comprising Angelica gigas Roots and Pueraria lobata Flowers Through the TLR2/6 Pathway in RAW 264.7 Macrophages and Cyclophosphamide-Induced Immunosuppression Mice
Seo-Yun Jang, Hyeon-A Song, Minji Park, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 336-336
Open Access
Protective effect of roflumilast on cyclophosphamide-induced ovarian toxicity in rats: role of SIRT1/Nrf2/nF-ĸB pathway
Salma A. El‐Marasy, Hadir Farouk, Marwa S. Khattab, et al.
Immunopharmacology and Immunotoxicology (2025), pp. 1-10
Closed Access
Synergistic Enhancement of Apo2L/TRAIL and DR4-Induced Apoptosis by Arsenic Trioxide in Triple-Negative Breast Cancer Cells: A Comparison to Conventional Chemotherapy
Soraya Moomivand, Mohsen Nikbakht, Ahmad Majd, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
Immune-Enhancing Effect of Sargassum horneri on Cyclophosphamide-Induced Immunosuppression in BALB/c Mice and Primary Cultured Splenocytes
Hyo In Kim, Dong-Sub Kim, Yunu Jung, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8253-8253
Open Access | Times Cited: 15
Toxoplasma gondii-derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide
Cherine A. Ismail, Maha M. Eissa, Maha R. Gaafar, et al.
Medical Oncology (2023) Vol. 40, Iss. 5
Open Access | Times Cited: 8
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
Bruno Almeida Costa, Tarek H. Mouhieddine, Ricardo J. Ortiz, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 187, pp. 104040-104040
Closed Access | Times Cited: 8
Fermentation of Ganoderma lucidum and Raphani Semen with a probiotic mixture attenuates cyclophosphamide-induced immunosuppression through microbiota-dependent or -independent regulation of intestinal mucosal barrier and immune responses
Yuyuan Li, Zengjie Lei, Yuling Guo, et al.
Phytomedicine (2023) Vol. 121, pp. 155082-155082
Open Access | Times Cited: 8
Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma
Fatemeh Sadat Shafiei, Saeid Abroun
Life Sciences (2024) Vol. 356, pp. 122989-122989
Closed Access | Times Cited: 3
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
Serika D. Naicker, Claire L. Feerick, Kevin Lynch, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 15
Current and Novel Alkylators in Multiple Myeloma
Fredrik Schjesvold, Albert Oriol
Cancers (2021) Vol. 13, Iss. 10, pp. 2465-2465
Open Access | Times Cited: 15
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
Evan Flietner, Zhi Wen, Adhithi Rajagopalan, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 9
The emerging role of melflufen and peptide-conjugates in multiple myeloma
Nour Moukalled, Iman Abou Dalle, Jean El Cheikh, et al.
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
The Role of DNA Repair in Genomic Instability of Multiple Myeloma
Jana Yasser Hafez Ali, Amira Fitieh, Ismail Hassan Ismail
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5688-5688
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top